Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Joseph R. Arron Clear advanced filters

  • Osteoporosis researchers do not suffer from a lack of potential drug targets—so one challenge is to decide which ones to focus on. Yongwon Choi, Matthew C. Walsh and Joseph R. Arron now examine several molecules involved in bone biology and assess their prospects. In a second commentary, Cliff Rosen analyzes findings that serotonin, derived from the gut, regulates bone formation. The findings not only could lead to new drug targets, they also could help explain clinical data that serotonin reuptake inhibitors—widely prescribed as antidepressants—weaken bones.

    • Yongwon Choi
    • Matthew C Walsh
    • Joseph R Arron
    Comments & Opinion
    Nature Medicine
    Volume: 15, P: 144-145

  • Age is associated with increasing vulnerability to both acute and chronic lung diseases. Employing genomic analysis and live lung imaging, this study reveals a profile of increased cellular senescence, telomere shortening, and fibrosis-induced impaired alveolar function in the natural history of human lung aging.

    • Seoyeon Lee
    • Mohammad Naimul Islam
    • Mallar Bhattacharya
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-10

  • This paper reports a chemical genetics strategy for regulating a developmental protein in a fetus in a reversible, time-controlled fashion. Remarkably, this control can be achieved in the mother's uterus. An existing chemically regulated allele of glycogen synthase kinase-3β (GSK-3β) is used, where the protein is fused to a tag, and its activity depends on the presence of rapamycin, which destabilizes the mutant.

    • Karen J. Liu
    • Joseph R. Arron
    • Michael T. Longaker
    Research
    Nature
    Volume: 446, P: 79-82

  • Single-cell and genetic tools are used to characterize the diversity of fibroblasts across healthy and perturbed tissues in mice and humans.

    • Matthew B. Buechler
    • Rachana N. Pradhan
    • Shannon. J. Turley
    Research
    Nature
    Volume: 593, P: 575-579

  • Current therapies for RA focus on inhibition of synovitis, but do not adequately repair the bone damage that results from the imbalance of the osteoblast–osteoclast axis. Targeting key molecules involved in osteoclastogenesis and osteoblastogenesis might reduce bone destruction and enhance repair of erosions in this disease.

    • Yongwon Choi
    • Joseph R. Arron
    • Michael J. Townsend
    Reviews
    Nature Reviews Rheumatology
    Volume: 5, P: 543-548

  • Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.

    • Michael J. Townsend
    • Joseph R. Arron
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 15, P: 517-518

  • An unprecedented number of potentially disruptive therapeutic technologies are under development. Forward-looking policies, incentives and infrastructure are needed to harness these advances to provide effective and globally equitable healthcare.

    • David J. Ecker
    • Clarice D. Aiello
    • Michael R. Hayden
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 23, P: 321-322

  • A molecule on activated T cells triggers bone loss by switching on bone-resorbing cells. Fortunately, it seems that this mechanism is kept in check by another molecule, secreted by the T cells.

    • Joseph R. Arron
    • Yongwon Choi
    News & Views
    Nature
    Volume: 408, P: 535-536